|
Dr Navin Saxena, a Ph. D in Synthetic Organic Chemistry
from the Moscow Friendship University started his career with Unichem
Laboratories Research Centre in 1981 as Research Officer and within
a short span of 10 years reached the level of Vice President and
Head of Research. During his tenure pioneering research was done
on life saving molecules like Buprenorphine, Nifedipine and Sucralfate
leading to them being developed for the first time in India on a
commercial scale. The process patent for Buprenorphine is held under
Dr Saxena's name.
In 1994 the "entrepreneurial" seed
was sown by Dr Saxena and he decided to venture on his own and started
Rusan Pharma Ltd. In 1996 he established his own research centre
in Mumbai. From a modest team of just 3 people in 1994, Rusan has
grown significantly to employ nearly 300 people consisting of a
number of Ph D's, post graduates, MBA's and Chartered Accountants.
In June 1997, in recognition of his contribution
to Medical Healthcare in Russia the International Academy of Sciences,
one of the premier Research Institutes of Europe conferred upon
Dr N. Saxena the title of "ACADEMICIAN" and presented
him with the Honourable Cross of the Academy. Dr. Saxena is not
only the youngest recipient of this award, but is also the first
Indian to receive this accolade.
On 29th July 1997, Dr. Navin Saxena in the capacity
of being the Chairman of Rusan Pharma Ltd. was honoured with "THE
INTERNATIONAL EXECLLENCE AWARD" by the Council for Small and
Medium Exporters for excellence in export of medicines.
Dr. Saxena was also awarded the prestigious
"UDYOG RATTAN AWARD" by the institute for Economic Studies
for his contribution in the field of Industrial development of India.
|
Dr
Navin Saxena 
